Inbrija (Levodopa)

Levodopa in Inbrija is absorbed through the lungs, enters the bloodstream, and crosses the blood‑brain barrier where it is converted to dopamine. This replenishes depleted central dopamine, improving the motor symptoms characteristic of Parkinson's disease.

The prescribed dose of Inbrija is determined by the treating physician based on the individual’s clinical condition and existing oral levodopa regimen. The prescriber decides the number of inhalations and frequency appropriate for each patient.

Safety data for Inbrija in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To request Inbrija, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Inbrija delivers levodopa directly to the bloodstream via inhalation, producing a faster onset of action compared with oral tablets, which must pass through the gastrointestinal tract. This rapid delivery can more effectively abort OFF episodes, while oral tablets remain the primary long‑term maintenance therapy.

Inbrija should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture and direct sunlight, and ensure the inhalation device is clean and dry before each use.

Inbrija is a dry‑powder inhalation product. The patient uses a single‑use inhaler device, loading a dose of powder and inhaling deeply as instructed. The device delivers the medication to the lungs, where it is absorbed into the systemic circulation.

Serious risks include dyskinesia (involuntary movements), orthostatic hypotension, hallucinations or psychosis, and rare pulmonary complications such as edema. Patients should be monitored for these events, especially when initiating therapy or adjusting concurrent Parkinson's medications.

Inbrija is contraindicated in patients with known hypersensitivity to levodopa or any excipients, those taking non‑selective MAO inhibitors, and individuals with severe respiratory disorders that could be worsened by inhaled powder. Caution is also advised for patients with uncontrolled cardiovascular disease.